BEAM 301 Shows Early Human Metabolic Correction

Company Beam Therapeutics Event Type Phase I/II initial clinical data Modality In vivo LNP-delivered base editing Asset BEAM-301 Target G6PC1 R83C allele Disease Area Glycogen storage disease type Ia Summary Beam reported initial Phase I/II human data for liver-directed base editing in glycogen storage disease…